Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 17,000 shares, a drop of 83.2% from the October 31st total of 101,000 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 379,700 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Evoke Pharma in a research report on Wednesday, November 20th. They issued a “sell” rating on the stock.
Check Out Our Latest Research Report on EVOK
Evoke Pharma Trading Down 0.5 %
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Quiet Period Expirations Explained
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What is MarketRankā¢? How to Use it
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.